Avax Technologies and Neptunus International Holdings Limited execute joint venture agreement to market AC Vaccine™ Technology

November 30, 1999

Company Contact: Jeffrey M. Jonas, MD AVAX Technologies, Inc. (816) 960-1333 Investors/Media: Olga Fleming/Sue Yeoh CPR Financial Communications (201) 641-2408 FOR IMMEDIATE RELEASE AVAX TECHNOLOGIES AND NEPTUNUS INTERNATIONAL HOLDINGS LIMITED EXECUTE JOINT VENTURE AGREEMENT TO MARKET AC VACCINE™ TECHNOLOGY IN AUSTRALIA AND NEW ZEALAND -AVAX Australia Pty. Ltd. Receives $3.6 Million (AUD) from NIHL to Begin Commercialization Process- - Joint Venture on Track to Market Melanoma Vaccine in 2000 - Kansas City, MO, December 1, 1999 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that it has executed its joint venture agreement with Neptunus International Holdings Limited (NIHL) in Australia, under the subsidiary name, AVAX Australia Pty. Ltd. AVAX Australia will manufacture and market AVAX's autologous cancer vaccine (AC Vaccine™) for melanoma, M-Vax™, in Australia and has similar rights in New Zealand. As part of the agreement, AVAX Australia has received $3.6 million (AUD) and will receive an additional $0.4 million (AUD) within thirty days from NIHL for the purchase of a 20% interest in the joint venture. NIHL also has the option to purchase an additional 30% interest for $6.0 million (AUD). Under the terms of the agreement, AVAX has also been granted options to purchase common stock equivalent to 5% of NIHL's fully diluted shares. In June 1999, AVAX announced that it had received notice from Australia's Therapeutic Goods Administration (TGA) that M-Vax may be made available for commercial sale, subject only to licensure of a manufacturing facility. M-Vax, AVAX's lead cancer vaccine, is currently in pivotal registration trials in the United States for patients with Stage III melanoma, a deadly form of skin cancer. Jeffrey M. Jonas, M.D., President and CEO of AVAX Technologies, Inc., stated, "We are very pleased to execute this important agreement with NIHL, another step in becoming the first company to market an autologous melanoma vaccine. We are very excited by the commercialization opportunities present in Australia, as this market allows us to demonstrate once again the validity of our business model and the ease of marketing a custom product. At this time, we are in the final stages of choosing a location for our clean-room facility, which will be the manufacturing and distribution center for M-Vax in Australia. We expect to begin the build-out of this facility by January 2000." M-Vax, a therapeutic cancer vaccine, is an essentially non-toxic, post-surgical experimental treatment for Stage III melanoma. To date, over 350 patients have been treated with M-Vax on an outpatient basis in the U.S. In Phase 2 studies, patients with Stage III melanoma demonstrated a five-year survival rate of 55%. AVAX Technologies, Inc. specializes in the development and commercialization of novel biotechnologies, immunotherapies and pharmaceuticals for cancer and other life-threatening diseases using three core technologies: the AC Vaccine technology, topoisomerase inhibitors and anti-estrogens. # # # Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the company will be achieved; in fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the company's ability to achieve the stated outcomes and to successfully develop and commercialize its product candidates, including, among other things, the ability to obtain substantial additional funds, obtain and maintain all necessary patents or licenses, to demonstrate the safety and efficacy of product candidates at each stage of development, to meet applicable regulatory standards and receive required regulatory approvals, to meet obligations and required milestones under its license agreements, to be capable of producing drug candidates in commercial quantities at reasonable costs, to compete successfully against other products, and to market products in a profitable manner, as well as other risks detailed from time to time in AVAX's public disclosure filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-KSB for the fiscal year ended December 31,1998. AVAX does not undertake any obligation to publicly release any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.

AVAX Technologies, Inc.

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.